Based on the benefits achieved for the treatment of other malignancies, CD47-targeting antibody and human (or murine) SIRPα-Fc have been used to access the anti-tumor effect of GBM by blocking CD47-SIRPα axis in vitro and in vivo. Here, SIRPA is linked to neoplasm.